HRP20120743T1 - Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja - Google Patents

Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja Download PDF

Info

Publication number
HRP20120743T1
HRP20120743T1 HRP20120743AT HRP20120743T HRP20120743T1 HR P20120743 T1 HRP20120743 T1 HR P20120743T1 HR P20120743A T HRP20120743A T HR P20120743AT HR P20120743 T HRP20120743 T HR P20120743T HR P20120743 T1 HRP20120743 T1 HR P20120743T1
Authority
HR
Croatia
Prior art keywords
disease
development
monitoring
inflammatory
assessing
Prior art date
Application number
HRP20120743AT
Other languages
English (en)
Croatian (hr)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of HRP20120743T1 publication Critical patent/HRP20120743T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
HRP20120743AT 2007-10-24 2008-10-15 Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja HRP20120743T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
HRP20120743T1 true HRP20120743T1 (hr) 2012-10-31

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120743AT HRP20120743T1 (hr) 2007-10-24 2008-10-15 Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
HRP20150181TT HRP20150181T1 (hr) 2007-10-24 2015-02-16 Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20150181TT HRP20150181T1 (hr) 2007-10-24 2015-02-16 Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja

Country Status (14)

Country Link
US (1) US20100209942A1 (enExample)
EP (2) EP2201376B1 (enExample)
JP (2) JP4982610B2 (enExample)
KR (2) KR20160029869A (enExample)
CA (1) CA2702635A1 (enExample)
CY (2) CY1113403T1 (enExample)
DK (2) DK2201376T3 (enExample)
ES (2) ES2532361T3 (enExample)
FI (1) FI20070795A0 (enExample)
HR (2) HRP20120743T1 (enExample)
PL (2) PL2503338T3 (enExample)
PT (2) PT2503338E (enExample)
SI (2) SI2503338T1 (enExample)
WO (1) WO2009053523A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878025C (en) 2008-01-18 2018-12-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
CA2806301A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
KR20150035818A (ko) 2012-06-15 2015-04-07 해리 스타일리 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
BR112015018213B1 (pt) * 2013-02-14 2022-12-20 Faron Pharmaceuticals Oy Métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0854934A4 (en) * 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
WO1997013875A1 (en) * 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
WO2002077174A2 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
PL1608400T3 (pl) * 2003-03-28 2010-11-30 Faron Pharmaceuticals Oy Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
EP1664073A2 (en) * 2003-06-03 2006-06-07 The Regents of the University of California Compositions and methods for treatment of disease with acetylated disaccharides
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof

Also Published As

Publication number Publication date
KR20160029869A (ko) 2016-03-15
EP2201376B1 (en) 2012-08-08
EP2503338A3 (en) 2013-03-13
DK2201376T3 (da) 2012-10-15
EP2201376A1 (en) 2010-06-30
CA2702635A1 (en) 2009-04-30
ES2389751T3 (es) 2012-10-31
JP2011501176A (ja) 2011-01-06
EP2201376A4 (en) 2011-03-23
PL2201376T3 (pl) 2013-01-31
CY1113403T1 (el) 2016-06-22
DK2503338T3 (en) 2015-03-09
CY1116089T1 (el) 2017-02-08
SI2503338T1 (sl) 2015-06-30
PT2503338E (pt) 2015-03-05
US20100209942A1 (en) 2010-08-19
EP2503338A2 (en) 2012-09-26
JP4982610B2 (ja) 2012-07-25
PL2503338T3 (pl) 2015-06-30
KR20100059902A (ko) 2010-06-04
JP2012159514A (ja) 2012-08-23
HRP20150181T1 (hr) 2015-06-19
EP2503338B1 (en) 2014-12-24
JP5619810B2 (ja) 2014-11-05
FI20070795A0 (fi) 2007-10-24
SI2201376T1 (sl) 2012-09-28
WO2009053523A1 (en) 2009-04-30
PT2201376E (pt) 2012-08-20
ES2532361T3 (es) 2015-03-26

Similar Documents

Publication Publication Date Title
HRP20120743T1 (hr) Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
Lopes et al. Acute kidney injury in HCT: an update
JP2011501176A5 (enExample)
JP2014144959A5 (enExample)
Wang et al. Risk factors for mortality in patients with septic acute kidney injury in intensive care units in Beijing, China: a multicenter prospective observational study
JP2009524829A5 (enExample)
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
DE60231814D1 (de) Diagnostische marker für ischämie und mortalitätsrisiken
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
JP2017536558A5 (enExample)
EA202091766A1 (ru) Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике
Zhang et al. S-adenosylmethionine inhibits the activated phenotype of human hepatic stellate cells via Rac1 and matrix metalloproteinases
JP2010502177A5 (enExample)
JP2015523364A5 (enExample)
WO2018236134A3 (en) METHOD AND KIT FOR THE DIAGNOSIS OF MUSCLE WEAK RELATED DISEASES USING A BLOOD BIOMARKER
JP2010502940A5 (enExample)
JP2013526863A5 (enExample)
JP2016512325A5 (enExample)
JP2008504228A5 (enExample)
Kumar et al. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project in New Delhi, India
JP2010502179A5 (enExample)
JP2016088926A5 (enExample)
Ryu et al. Clinical features of ischemic colitis: a comparision with colonoscopic findings
Mizoguchi et al. Animal models of inflammatory bowel disease for drug discovery